Abstract
Breast cancer is a complex and heterogeneous disease that poses a significant public health concern worldwide, and it remains a major challenge despite advances in treatment options. One of the main properties of cancer cells is the increased proliferative activity that has lost regulation. Dysregulation of various positive and negative modulators in the cell cycle has been identified as one of the driving factors of breast cancer. In recent years, non-coding RNAs have garnered much attention in the regulation of cell cycle progression, with microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs) being of particular interest. MiRNAs are a class of highly conserved and regulatory small non-coding RNAs that play a crucial role in the modulation of various cellular and biological processes, including cell cycle regulation. CircRNAs are a novel form of non-coding RNAs that are highly stable and capable of modulating gene expression at posttranscriptional and transcriptional levels. LncRNAs have also attracted considerable attention because of their prominent roles in tumor development, including cell cycle progression. Emerging evidence suggests that miRNAs, circRNAs and lncRNAs play important roles in the regulation of cell cycle progression in breast cancer. Herein, we summarized the latest related literatures in breast cancer that emphasize the regulatory roles of miRNAs, circRNAs and lncRNAs in cell cycle progress of breast cancer. Further understanding of the precise roles and mechanisms of non-coding RNAs in breast cancer cell cycle regulation could lead to the development of new diagnostic and therapeutic strategies for breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bardhan A, Banerjee A, Basu K, Pal DK, Ghosh A (2022) PRNCR1: a long non-coding RNA with a pivotal oncogenic role in cancer. Hum Genet 141:15–29. https://doi.org/10.1007/s00439-021-02396-8
Barnum KJ, O’Connell MJ (2014) Cell cycle regulation by checkpoints. Methods Mol Biol 1170:29–40. https://doi.org/10.1007/978-1-4939-0888-2_2
Bida O, Gidoni M, Ideses D, Efroni S, Ginsberg D (2015) A novel mitosis-associated lncRNA, MA-linc1, is required for cell cycle progression and sensitizes cancer cells to Paclitaxel. Oncotarget 6:27880–27890. https://doi.org/10.18632/oncotarget.4944
Boon RA, Jae N, Holdt L, Dimmeler S (2016) Long Noncoding RNAs: From Clinical Genetics to Therapeutic Targets? J Am Coll Cardiol 67:1214–1226. https://doi.org/10.1016/j.jacc.2015.12.051
Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL (2011) Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 25:1915–1927. https://doi.org/10.1101/gad.17446611
Cai F, Fu W, Tang L, Tang J, Sun J, Fu G, Ye G (2021) Hsa_circ_0000515 is a novel circular RNA implicated in the development of breast cancer through its regulation of the microRNA-296-5p/CXCL10 axis. FEBS J 288:861–883. https://doi.org/10.1111/febs.15373
Chakravarty D, Sboner A, Nair SS et al (2014) The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun 5:5383. https://doi.org/10.1038/ncomms6383
Chen DQ, Zheng XD, Cao Y, He XD, Nian WQ, Zeng XH, Liu XY (2017) Long non-coding RNA LINC00628 suppresses the growth and metastasis and promotes cell apoptosis in breast cancer. Eur Rev Med Pharmacol Sci 21:275–283. https://www.ncbi.nlm.nih.gov/pubmed/28165561
Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA (2022) Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther 7:121. https://doi.org/10.1038/s41392-022-00975-3
Crichton DJ, Altinok A, Amos CI et al (2020) Cancer Biomarkers and Big Data: A Planetary Science Approach. Cancer Cell 38:757–760. https://doi.org/10.1016/j.ccell.2020.09.006
Cui Y, Lu C, Zhang Z et al (2020) A Long Non-coding RNA Lnc712 Regulates Breast Cancer Cell Proliferation. Int J Biol Sci 16:162–171. https://doi.org/10.7150/ijbs.36429
Cui M, Liu Y, Cui L (2022) Long non-coding RNA LINC02613 is a prognostic biomarker for breast cancer and correlates with the cell cycle and immune infiltration based on TCGA data. Transl Cancer Res 11:615–628. https://doi.org/10.21037/tcr-21-2479
Deng J, Yang M, Jiang R, An N, Wang X, Liu B (2017) Long Non-Coding RNA HOTAIR Regulates the Proliferation, Self-Renewal Capacity, Tumor Formation and Migration of the Cancer Stem-Like Cell (CSC) Subpopulation Enriched from Breast Cancer Cells. Plos One 12:e0170860. https://doi.org/10.1371/journal.pone.0170860
Deniz E, Erman B (2017) Long noncoding RNA (lincRNA), a new paradigm in gene expression control. Funct Integr Genomics 17:135–143. https://doi.org/10.1007/s10142-016-0524-x
Fan S, Yang Z, Ke Z, Huang K, Liu N, Fang X, Wang K (2017) Downregulation of the long non-coding RNA TUG1 is associated with cell proliferation, migration, and invasion in breast cancer. Biomed Pharmacother 95:1636–1643. https://doi.org/10.1016/j.biopha.2017.09.076
Florea AM, Busselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (basel) 3:1351–1371. https://doi.org/10.3390/cancers3011351
Fu M, Wang C, Li Z, Sakamaki T, Pestell RG (2004) Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145:5439–5447. https://doi.org/10.1210/en.2004-0959
Gascoigne KE, Taylor SS (2009) How do anti-mitotic drugs kill cancer cells? J Cell Sci 122:2579–2585. https://doi.org/10.1242/jcs.039719
Ghafouri-Fard S, Khoshbakht T, Hussen BM, Taheri M, Samadian M (2022) A review on the role of MCM3AP-AS1 in the carcinogenesis and tumor progression. Cancer Cell Int 22:225. https://doi.org/10.1186/s12935-022-02644-5
Guo S, Jian L, Tao K, Chen C, Yu H, Liu S (2019) Novel Breast-Specific Long Non-coding RNA LINC00993 Acts as a Tumor Suppressor in Triple-Negative Breast Cancer. Front Oncol 9:1325. https://doi.org/10.3389/fonc.2019.01325
Hajjari M, Salavaty A (2015) HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med 12:1–9. https://doi.org/10.7497/j.issn.2095-3941.2015.0006
Hallstrom TC, Nevins JR (2009) Balancing the decision of cell proliferation and cell fate. Cell Cycle 8:532–535. https://doi.org/10.4161/cc.8.4.7609
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495:384–388. https://doi.org/10.1038/nature11993
Hassan MS, Ansari J, Spooner D, Hussain SA (2010) Chemotherapy for breast cancer (Review). Oncol Rep 24:1121–1131. https://doi.org/10.3892/or_00000963
Heidari R, Akbariqomi M, Asgari Y, Ebrahimi D, Alinejad-Rokny H (2021) A systematic review of long non-coding RNAs with a potential role in breast cancer. Mutat Res Rev Mutat Res 787:108375. https://doi.org/10.1016/j.mrrev.2021.108375
Horwitz KB, Sartorius CA (2020) 90 YEARS OF PROGESTERONE: Progesterone and progesterone receptors in breast cancer: past, present, future. J Mol Endocrinol 65:T49–T63. https://doi.org/10.1530/JME-20-0104
Iorio MV, Ferracin M, Liu CG et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065–7070. https://doi.org/10.1158/0008-5472.CAN-05-1783
Irani S, Paknejad M, Soleimani M, Azam S (2020) Evaluation of miR-34a Effect on CCND1 mRNA Level and Sensitization of Breast Cancer Cell Lines to Paclitaxel. Iran Biomed J 24:361–369. https://doi.org/10.29252/ibj.24.6.356
Ji W, Zhang W, Wang X et al (2020) c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis. Cell Death Dis 11:760. https://doi.org/10.1038/s41419-020-02980-2
Jiang YZ, Liu YR, Xu XE, Jin X, Hu X, Yu KD, Shao ZM (2016) Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. Cancer Res 76:2105–2114. https://doi.org/10.1158/0008-5472.CAN-15-3284
Kesharwani P, Gajbhiye V, Jain NK (2012) A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 33:7138–7150. https://doi.org/10.1016/j.biomaterials.2012.06.068
Khan S, Brougham CL, Ryan J et al (2013) miR-379 regulates cyclin B1 expression and is decreased in breast cancer. Plos One 8:e68753. https://doi.org/10.1371/journal.pone.0068753
Kitagawa M, Kitagawa K, Kotake Y, Niida H, Ohhata T (2013) Cell cycle regulation by long non-coding RNAs. Cell Mol Life Sci 70:4785–4794. https://doi.org/10.1007/s00018-013-1423-0
Kretz M, Siprashvili Z, Chu C et al (2013) Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature 493:231–235. https://doi.org/10.1038/nature11661
Lee RJ, Albanese C, Fu M et al (2000) Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 20:672–683. https://doi.org/10.1128/MCB.20.2.672-683.2000
Li R, Zheng X, Popov I et al (2012) Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J Transl Med 10:19. https://doi.org/10.1186/1479-5876-10-19
Li Z, Yu D, Li H, Lv Y, Li S (2019) Long non-coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. Int J Oncol 54:1033–1042. https://doi.org/10.3892/ijo.2019.4679
Li X, Ren Z, Yao Y, Bao J, Yu Q (2020) The circular RNA circEIF3M promotes breast cancer progression by promoting cyclin D1 expression. Aging (Albany NY) 12:14775–14790. https://doi.org/10.18632/aging.103539
Lin G, Wang S, Zhang X, Wang D (2020) Circular RNA circPLK1 promotes breast cancer cell proliferation, migration and invasion by regulating miR-4500/IGF1 axis. Cancer Cell Int 20:593. https://doi.org/10.1186/s12935-020-01694-x
Liu J, Carmell MA, Rivas FV et al (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305:1437–1441. https://doi.org/10.1126/science.1102513
Liu M, Xing LQ, Liu YJ (2017) A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers. Medicine (Baltimore) 96:e6222. https://doi.org/10.1097/MD.0000000000006222
Liu Y, Lu C, Zhou Y, Zhang Z, Sun L (2018) Circular RNA hsa_circ_0008039 promotes breast cancer cell proliferation and migration by regulating miR-432-5p/E2F3 axis. Biochem Biophys Res Commun 502:358–363. https://doi.org/10.1016/j.bbrc.2018.05.166
Liu LH, Tian QQ, Liu J, Zhou Y, Yong H (2019) Upregulation of hsa_circ_0136666 contributes to breast cancer progression by sponging miR-1299 and targeting CDK6. J Cell Biochem 120:12684–12693. https://doi.org/10.1002/jcb.28536
Lu D, Di S, Zhuo S et al (2021) The long noncoding RNA TINCR promotes breast cancer cell proliferation and migration by regulating OAS1. Cell Death Discov 7:41. https://doi.org/10.1038/s41420-021-00419-x
Luo Q, Li X, Gao Y, Long Y, Chen L, Huang Y, Fang L (2013) MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer. Cancer Cell Int 13:95. https://doi.org/10.1186/1475-2867-13-95
Malumbres M (2014) Cyclin-dependent kinases. Genome Biol 15:122. https://doi.org/10.1186/gb4184
Matsuyama T, Kandimalla R, Ishikawa T et al (2020) A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer. Int J Cancer 147:3250–3261. https://doi.org/10.1002/ijc.33129
Miller TE, Ghoshal K, Ramaswamy B et al (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283:29897–29903. https://doi.org/10.1074/jbc.M804612200
Montagna E, Maisonneuve P, Rotmensz N et al (2013) Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer 13:31–39. https://doi.org/10.1016/j.clbc.2012.09.002
Nahta R, Al-Mulla F, Al-Temaimi R et al (2015) Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. Carcinogenesis 36(Suppl 1):S2-18. https://doi.org/10.1093/carcin/bgv028
Niu Y, Xu J, Sun T (2019) Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies. J Cancer 10:5504–5517. https://doi.org/10.7150/jca.32628
Nurse P, Masui Y, Hartwell L (1998) Understanding the cell cycle. Nat Med 4:1103–1106. https://doi.org/10.1038/2594
Orban TI, Izaurralde E (2005) Decay of mRNAs targeted by RISC requires XRN1, the Ski complex, and the exosome. RNA 11:459–469. https://doi.org/10.1261/rna.7231505
Ouyang J, Liu Z, Yuan X et al (2021) LncRNA PRNCR1 Promotes Breast Cancer Proliferation and Inhibits Apoptosis by Modulating microRNA-377/CCND2/MEK/MAPK Axis. Arch Med Res 52:471–482. https://doi.org/10.1016/j.arcmed.2021.01.007
Park S, Koo JS, Kim MS et al (2012) Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 21:50–57. https://doi.org/10.1016/j.breast.2011.07.008
Pei W, Li X, Bi R et al (2021) Exosome membrane-modified M2 macrophages targeted nanomedicine: Treatment for allergic asthma. J Control Release 338:253–267. https://doi.org/10.1016/j.jconrel.2021.08.024
Peng X, Yan B, Shen Y (2018) MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1. Breast Cancer 25:742–752. https://doi.org/10.1007/s12282-018-0881-5
Pines J, Hunter T (1990) Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B. Nature 346:760–763. https://doi.org/10.1038/346760a0
Qiu X, Dong J, Zhao Z, Li J, Cai X (2019) LncRNA LINC00668 promotes the progression of breast cancer by inhibiting apoptosis and accelerating cell cycle. Onco Targets Ther 12:5615–5625. https://doi.org/10.2147/OTT.S188933
Romero-Pozuelo J, Figlia G, Kaya O, Martin-Villalba A, Teleman AA (2020) Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1. Cell Rep 31:107504. https://doi.org/10.1016/j.celrep.2020.03.068
Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A, Yee H, Sorich J, Speyer JL, Newcomb EW (2001) Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol 32:808–813. https://doi.org/10.1053/hupa.2001.26462
Said MN, Muawia S, Helal A, Fawzy A, Allam RM, Shafik NF (2021) Regulation of CDK inhibitor p27 by microRNA 222 in breast cancer patients. Exp Mol Pathol 123:104718. https://doi.org/10.1016/j.yexmp.2021.104718
Shen H, Wang D, Li L et al (2017) MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Gene 596:110–118. https://doi.org/10.1016/j.gene.2016.10.016
Shin VY, Chen J, Cheuk IW et al (2019) Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death Dis 10:270. https://doi.org/10.1038/s41419-019-1513-5
Si H, Chen P, Li H, Wang X (2019) Long non-coding RNA H19 regulates cell growth and metastasis via miR-138 in breast cancer. Am J Transl Res 11:3213–3225. https://www.ncbi.nlm.nih.gov/pubmed/31217890
Silva PM, Ribeiro N, Lima RT et al (2017) Suppression of spindly delays mitotic exit and exacerbates cell death response of cancer cells treated with low doses of paclitaxel. Cancer Lett 394:33–42. https://doi.org/10.1016/j.canlet.2017.02.024
Song JJ, Smith SK, Hannon GJ, Joshua-Tor L (2004) Crystal structure of Argonaute and its implications for RISC slicer activity. Science 305:1434–1437. https://doi.org/10.1126/science.1102514
St Laurent G, Wahlestedt C, Kapranov P (2015) The Landscape of long noncoding RNA classification. Trends Genet 31:239–251. https://doi.org/10.1016/j.tig.2015.03.007
Su Q, Shen H, Gu B, Zhu N (2022) miR-204-5p Hampers Breast Cancer Malignancy and Affects the Cell Cycle by Targeting PRR11. Comput Math Methods Med 2022:4010947. https://doi.org/10.1155/2022/4010947
Tang L, Jiang B, Zhu H et al (2021) The Biogenesis and Functions of circRNAs and Their Roles in Breast Cancer. Front Oncol 11:605988. https://doi.org/10.3389/fonc.2021.605988
Tang TP, Qin CX, Yu H (2021) MCM3AP-AS1 regulates proliferation, apoptosis, migration, and invasion of breast cancer cells via binding with ZFP36. Transl Cancer Res 10:4478–4488. https://doi.org/10.21037/tcr-21-1940
Thu KL, Soria-Bretones I, Mak TW, Cescon DW (2018) Targeting the cell cycle in breast cancer: towards the next phase. Cell Cycle 17:1871–1885. https://doi.org/10.1080/15384101.2018.1502567
Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A (2014) Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg 259:735–743. https://doi.org/10.1097/SLA.0b013e3182a6909d
Tolaney SM, Kalinsky K, Kaklamani VG et al (2021) Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. Clin Cancer Res 27:3061–3068. https://doi.org/10.1158/1078-0432.CCR-20-4726
Tormo E, Ballester S, Adam-Artigues A et al (2019) The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Sci Rep 9:5316. https://doi.org/10.1038/s41598-019-41472-y
Tovar-Camargo OA, Toden S, Goel A (2016) Exosomal microRNA Biomarkers: Emerging Frontiers in Colorectal and Other Human Cancers. Expert Rev Mol Diagn 16:553–567. https://doi.org/10.1586/14737159.2016.1156535
Tsuda Y, Iimori M, Nakashima Y et al (2017) Mitotic slippage and the subsequent cell fates after inhibition of Aurora B during tubulin-binding agent-induced mitotic arrest. Sci Rep 7:16762. https://doi.org/10.1038/s41598-017-17002-z
Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20:515–524. https://doi.org/10.1101/gad.1399806
Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X, Li X (2012) Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol 41:276–284. https://doi.org/10.3892/ijo.2012.1443
Wang D, Liu K, Chen E (2020) LINC00511 promotes proliferation and invasion by sponging miR-515-5p in gastric cancer. Cell Mol Biol Lett 25:4. https://doi.org/10.1186/s11658-020-0201-x
Wang L, Yi J, Lu LY et al (2021) Estrogen-induced circRNA, circPGR, functions as a ceRNA to promote estrogen receptor-positive breast cancer cell growth by regulating cell cycle-related genes. Theranostics 11:1732–1752. https://doi.org/10.7150/thno.45302
Wen D, Danquah M, Chaudhary AK, Mahato RI (2015) Small molecules targeting microRNA for cancer therapy: Promises and obstacles. J Control Release 219:237–247. https://doi.org/10.1016/j.jconrel.2015.08.011
Weng W, Wei Q, Toden S et al (2017) Circular RNA ciRS-7-A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer. Clin Cancer Res 23:3918–3928. https://doi.org/10.1158/1078-0432.CCR-16-2541
Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST (2004) Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 279:17181–17189. https://doi.org/10.1074/jbc.M311683200
Wu B, Zhang Y, Yu Y et al (2021) Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways. Front Cell Dev Biol 9:796740. https://doi.org/10.3389/fcell.2021.796740
Xie D, Song H, Wu T et al (2018) MicroRNA-424 serves an anti-oncogenic role by targeting cyclin-dependent kinase 1 in breast cancer cells. Oncol Rep 40:3416–3426. https://doi.org/10.3892/or.2018.6741
Yang R, Xing L, Zheng X, Sun Y, Wang X, Chen J (2019) The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression. Mol Cancer 18:4. https://doi.org/10.1186/s12943-018-0933-7
Yared JA, Tkaczuk KH (2012) Update on taxane development: new analogs and new formulations. Drug Des Devel Ther 6:371–384. https://doi.org/10.2147/DDDT.S28997
Young TL, Matsuda T, Cepko CL (2005) The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina. Curr Biol 15:501–512. https://doi.org/10.1016/j.cub.2005.02.027
Yu Z, Wang C, Wang M et al (2008) A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 182:509–517. https://doi.org/10.1083/jcb.200801079
Yu Y, Lv F, Liang D et al (2017) HOTAIR may regulate proliferation, apoptosis, migration and invasion of MCF-7 cells through regulating the P53/Akt/JNK signaling pathway. Biomed Pharmacother 90:555–561. https://doi.org/10.1016/j.biopha.2017.03.054
Yuan H, Qin Y, Zeng B, Feng Y, Li Y, Xiang T, Ren G (2019) Long noncoding RNA LINC01089 predicts clinical prognosis and inhibits cell proliferation and invasion through the Wnt/beta-catenin signaling pathway in breast cancer. Onco Targets Ther 12:4883–4895. https://doi.org/10.2147/OTT.S208830
Zhang H, Zhao B, Wang X, Zhang F, Yu W (2019) LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis. Life Sci 228:135–144. https://doi.org/10.1016/j.lfs.2019.04.063
Zhang D, Cai X, Cai S, Chen W, Hu C (2020a) Long Intergenic Non-Protein Coding RNA 01089 Weakens Tumor Proliferation, Migration, and Invasion by Sponging miR-3187-3p in Non-Small Cell Lung Cancer. Cancer Manag Res 12:12151–12162. https://doi.org/10.2147/CMAR.S258532
Zhang MC, Zhang L, Zhang MQ, Yang GX, Wang FZ, Ding P (2020) Downregulated LINC00628 aggravates the progression of colorectal cancer via inhibiting p57 level. Eur Rev Med Pharmacol Sci 24:1763–1770. https://doi.org/10.26355/eurrev_202002_20353
Zhao J, Zou H, Han C, Ma J, Zhao J, Tang J (2018) Circlular RNA BARD1 (Hsa_circ_0001098) overexpression in breast cancer cells with TCDD treatment could promote cell apoptosis via miR-3942/BARD1 axis. Cell Cycle 17:2731–2744. https://doi.org/10.1080/15384101.2018.1556058
Zhu X, Qiu J, Zhang T et al (2020) MicroRNA-188-5p promotes apoptosis and inhibits cell proliferation of breast cancer cells via the MAPK signaling pathway by targeting Rap2c. J Cell Physiol 235:2389–2402. https://doi.org/10.1002/jcp.29144
Davey MG, Davies M, Lowery AJ, Miller N, Kerin MJ (2021) The Role of MicroRNA as Clinical Biomarkers for Breast Cancer Surgery and Treatment. Int J Mol Sci 22. https://doi.org/10.3390/ijms22158290
Ding L, Cao J, Lin W et al. (2020) The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int J Mol Sci 21. https://doi.org/10.3390/ijms21061960
Hu X, Ding D, Zhang J, Cui J (2019) Knockdown of lncRNA HOTAIR sensitizes breast cancer cells to ionizing radiation through activating miR-218. Biosci Rep 39. 10.1042/BSR20181038
Lane JS, Hoff DV, Cridebring D, Goel A (2020) Extracellular Vesicles in Diagnosis and Treatment of Pancreatic Cancer: Current State and Future Perspectives. Cancers (Basel) 12. https://doi.org/10.3390/cancers12061530
Loh HY, Norman BP, Lai KS, Rahman N, Alitheen NBM, Osman MA (2019) The Regulatory Role of MicroRNAs in Breast Cancer. Int J Mol Sci 20. https://doi.org/10.3390/ijms20194940
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
SH contributed to conception and design. HC, GX and QL made the literature searching. HC and SH drafted the manuscript. SH, HC and YY prepared the figure and tables. HC, GX, YY and SH revised the manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent participate
Not applicable.
Animal ethics
Not applicable.
Conflicts of Interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chen, H., Xie, G., Luo, Q. et al. Regulatory miRNAs, circRNAs and lncRNAs in cell cycle progression of breast cancer. Funct Integr Genomics 23, 233 (2023). https://doi.org/10.1007/s10142-023-01130-z
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10142-023-01130-z